Corvus Pharmaceuticals (STU:C17) Change In Payables And Accrued Expense : €-1.25 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Change In Payables And Accrued Expense?

Corvus Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €0.17 Mil. It means Corvus Pharmaceuticals's Accounts Payable & Accrued Expense increased by €0.17 Mil from Dec. 2023 to Mar. 2024 .

Corvus Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €-3.70 Mil. It means Corvus Pharmaceuticals's Accounts Payable & Accrued Expense declined by €3.70 Mil from Dec. 2022 to Dec. 2023 .

Corvus Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Corvus Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Change In Payables And Accrued Expense Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

2.24

1.42

-2.15

0.83

-3.70

Corvus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-2.33	-0.43	-0.56	-0.43	0.17

Corvus Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.25 Mil.

Corvus Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals (STU:C17) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (STU:C17) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Corvus Pharmaceuticals (STU:C17) Headlines

No Headlines